SB 202026: A novel muscarinic partial agonist with functional selectivity for M1 receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 283, Issue 3, 1997, Pages 1059-1068

  Loudon, J M ^a   Bromidge, S M ^a   Brown, F ^a   Clark, M S G ^a   Hatcher, J P ^a   Hawkins, J ^a   Riley, G J ^a   Noy, G ^a   Orlek, B S ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA (METHYOXIMINO) 1 AZABICYCLO[2.2.2] OCTANE 3 ACETONITRILE; ARECOLINE; BENZILIC ACID; CARBACHOL; CEVIMELINE; KETANSERIN; MESULERGINE; METHOCTRAMINE; MUSCARINIC AGENT; OXOTREMORINE; PIRENZEPINE; SABCOMELINE; SPIPERONE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; COGNITION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; MEMBRANE DEPOLARIZATION; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION;

ACETYLCHOLINE; ANIMALS; CHO CELLS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; GUINEA PIGS; HEMODYNAMIC PROCESSES; HUMANS; ILEUM; IMINES; MALE; MICE; MUSCARINIC AGONISTS; QUINUCLIDINES; RATS; RECEPTOR, MUSCARINIC M1; RECEPTORS, MUSCARINIC;

EID: 0031441919     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (88)

1. ARAUJO, D. M., LAPCHAK, P. A., ROBITAILLE, Y., GAUTHIER, S. AND QUIRION, R.: Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. J. Neurochem. 50(6): 1914-1923, 1988.
2. ARIENS, E. J.: Intrinsic activity: Partial agonists and partial antagonists. J. Cardiovas. Pharmacol. 5: S8-S15, 1983.
3. BARNES, J. C. AND ROBERTS, F. F.: Central effects of muscarinic agonists and antagonists on hippocampal theta rhythm and blood pressure in the anaesthetised rat. Eur. J. Pharmacol. 195: 233-240, 1991.
4. BAUM, T.: Fundamental principles governing regulation of circulatory function. In Cardiovascular Pharmacology, 1-35, Raven Press, New York, 1990.
5. BECKER, R. E. AND GIACOBINI, E.: Mechanisms of cholinesterase inhibition in senile dementia of the Alzheimer type: Clinical, pharmacological and therapeutic aspects. Drug Dev. Res. 12: 163-195, 1988.
6. BEVAN, P.: [3H] oxotremorine-M binding to membranes prepared from rat brain and heart: Evidence for subtypes of muscarinic receptors. European J. Pharmacol. 101: 101-110, 1984a.
7. BEVAN, P.: Effects of muscarinic ligands on the electrical activity recorded from the hippocampus: A quantitative approach. Br. J. Pharmacol. 82: 431-440, 1984b.
8. BILLARD, W., RUPERTO, V., CROSBY, G., IORIO, L. C. AND BARNETT, A.: Characterisation of the binding of 3H-SCH23390, a selective D-1 receptor antagonist ligand, in rat striatum. Life Sci. 35: 1885-1893, 1984.
9. BODDEKE, H. W. G. M.: Different effects of muscarinic agonists in rat superior cervical ganglion and hippocampal slices. Eur. J. Pharm. 201: 191-197, 1991.
10. BONNER, T. I., BUCKLEY, N. J., YOUNG, A. C. AND BRANN, M. R.: Identification of a family of muscarinic acetylcholine receptor genes. Science (Wash. DC) 237: 527-532, 1987.
11. BONNER, T. I., BUCKLEY, N. J., YOUNG, A. C. AND BRANN, M. R.: Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron 1: 403-410, 1988.
12. BOWEN, D. M.: Biochemical assessment of neurotransmitter and metabolic dysfunction and cerebral atrophy in Alzheimer's disease. In Banbury Report 15, ed. by R. Katzman, pp. 219-232, Cold Spring Harbor, New York, 1983.
13. BREZENOFF, H. E. AND GIULIANO, R.: Cardiovascular control by cholinergic mechanisms in the central nervous system. Ann. Rev. Pharmacol. Toxicol. 22: 341-381, 1982.
14. BROWN, F., CLARK, M., GRAVES, D., HADLEY, M., HATCHER, J., MCARTHUR, R., RILEY, G. AND SEMPLE, J.: Variations of muscarinic activities of oxotremorine analogues. Drug Dev. Res. 14: 343-347, 1988a.
15. BROWN, F., CAMPBELL, W., CLARK, M. S. G., GRAVES, D. S., HADLEY, M. S., HATCHER, J., MITCHELL, P., NEEDHAM, P., RILEY, G. AND SEMPLE, J.: The selective dopamine antagonist properties of BRL34778: A novel substituted benzamide. Psychopharmacol. 94: 350-358, 1988b.
16. BUCKLEY, N. J., BONNER, T. I., BUCKLEY, C. M. AND BRANN, M. R.: Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol. Pharmacol. 35: 469-476, 1989.
17. CAULFIELD, M. P.: Muscarinic receptors - characterization, coupling and function. Pharmac. Ther. 58: 219-379, 1993.
18. CLAGUE, R. U., EGLEN, R. M., STRACHAN, A. C. AND WHITING, R. L.: Action of agonists and antagonists at muscarinic receptors present on ileum and atria in vitro. Br. J. Pharmacol. 86: 163-170, 1985.
19. CLARK, M. S. G., BROWN, F., HARRIES, M., HATCHER, J., HAWKINS, J., LOUDON, J. M., NOY, G. AND RILEY, G.: SB 202026: A muscarinic partial agonist with functional selectivity for M1 receptors. Neurobiology of Aging, 17 (4F): S161, 1996.
20. COOPER, S. M., KUMAR, R., HIGGINS, R., ZUSSMAN, B., DAVIE, C. AND CYRONAK, M.: Safety, tolerability and pharmacokinetics of SB 202026 in man. Neurobiology of Aging 17 (4F): S30, 1996.
21. CORTES, R., PROBST, A. AND PALACIOS, J. M.: Quantitative light microscopic autoradiographic localization of cholinergic muscarinic receptors in the human brain: Forebrain. Neuroscience 20(1): 65-107, 1987.
22. DOODS, H. N., MATHY, M-J., DAVIDESKO, D., VAN CHARLDORP, K. J., DE JONGE, A. AND VAN ZWIETEN, P. A.: Selectivity of muscarinic antagonists in radioligand and in vivo experiments for the putative M1, M2 and M3 receptors. JPET 242(1): 257-262, 1987.
23. DUNNETT, S. B. AND FIBIGER, H. C.: Role of forebrain cholinergic systems in learning and memory: Relevance to the cognitive deficits of aging and Alzheimer's disease. Prog. Brain. Res. 98: 413-420, 1993.
24. DURKIN, T.: Central cholinergic pathways and learning and memory processes: Presynaptic aspects. Comp. Biochem. Physiol. 93A(1): 273-280, 1989.
25. EGLEN, R. M. AND WATSON, N.: Selective muscarinic receptor agonists and antagonists. Pharmacol. Toxicol. 78: 59-68, 1996.
26. EGLEN, R. M. AND WHITING, R. L.: Heterogeneity of vascular muscarinic receptors. J. Auton. Pharmacol. 19: 233-245, 1990.
27. ENSINGER, H. A., DOODS, H. N., IMMEL-SEHR, A. R., KUHN, F. J., LAMBRECHT, G., MENDLA, K. D., MUELLER, R. E., MUTSCHLER, E., SAGRADA, A., WALTHER, G. AND HAMMER, R.: WAL 2014 - a muscarinic agonist with preferential neuron-stimulating properties. Life Sci. 52: 473-480, 1993.
28. ENZ, A., SHAPIRO, G., SUPAVILAI, P. AND BODDEKE, H. W. G. M.: SDZ ENS 163 is a selective M1 agonist and induces release of acetylcholine. Naunyn-Schmiedeberg's Arch. Pharmacol. 345: 282-287, 1992.
29. FLIER, J. S. AND UNDERHILL, L. H.: Muscarinic receptor subtypes: Physiology and clinical implications. N. Engl. J. Med. 321(15): 1022-1028, 1989.
30. 3H]-methylscopolamine afford differential labeling and localization of M1, M2 and M3 muscarinic receptor subtypes in primate brain. Synapse 14: 283-296, 1993.
31. FREEDMAN, S. B., HARLEY, E. A. AND IVERSEN, L. L.: Relative affinities of drugs acting at cholinoceptors in displacing agonist and antagonist radioligands: The NMS/Oxo-M ratio as an index of efficacy at cortical muscarinic receptors. Br. J. Pharmacol. 93: 437-445, 1988.
32. FREEDMAN, S. B., DAWSON, G. R., IVERSEN, L. L., BAKER, R. AND HARGREAVES, R. J.: The design of novel muscarinic partial agonists that have functional selectivity in pharmacological preparations in vitro and reduced side effect profile in vivo. Life Sci. 52(5/6): 489-495, 1993.
33. FURCHGOTT, R. F. AND BURSZTYN, P.: Comparison of dissociation constants and of relative efficacies of selected agonists acting on parasympathetic receptors. Ann. N.Y. Acad. Sci. 144: 882-899, 1967.
34. GEE, K. W., LAWRENCE, L. J. AND YAMAMURA, H. I.: Modulation of the chloride ionophore by benzodiazepine receptor ligands: Influence of gamma-aminobutyric acid and ligand efficacy. Mol. Pharmacol. 30: 218-225, 1986.
35. HAGAN, J. J., JANSEN, J. H. M. AND BROEKKAMP, C. L. E.: Blockade of spatial learning by the M1 muscarinic antagonist pirenzepine. Psychopharmacology 93: 470-476, 1987.
36. HAGAN, J. J. AND MORRIS, R. G. M.: The cholinergic hypothesis of memory: A review of animal experiments. Handbook of Psychopharmacology 20: 237-323, 1988.
37. HARGREAVES, R. J., MCKNIGHT, A. T., SCHOLEY, K., NEWBERRY, N. R., STREET, L. J., HUTSON, P. H., SEMARK, J. E., HARLEY, E. A., PATEL, S. AND FREEDMAN, S. B.: L-689,660, a novel cholinomimetic with functional selectivity for M1 and M3 receptors. Br. J. Pharmacol. 107: 494-501, 1992.
38. HARRISON, P. J., BARTON, A. J. L., NAJLERAHIM, A., MCDONALD, B. AND PEARSON, R. C. A.: Increased muscarinic receptor messenger RNA in Alzheimer's disease temporal cortex demonstrated by in situ hybridization histochemistry. Mol. Brain Res. 9: 15-21, 1991.
39. HAWKINS, J., RILEY, G. J., BROWN, F. AND CLARK, M. S. G.: Neurodegeneration of the Alzheimer type: Muscarinic agonists for counteracting the acetylcholine deficit. Selectivity studies on human muscarinic receptor subtypes hm1-hm4 expressed in CHO cells. In Neurodegeneration, ed. by A. J. Hunter and M. S. G. Clark, pp. 240-241, Academic Press, London, 1992.
40. 3H]-5-hydroxytryptamine binding site subtype in bovine brain membranes. J. Neurosci. 7: 894-903, 1987.
41. HOLLANDER, E., DAVIDSON, M., MOHS, R. C., HORVATH, T. B., DAVIS, B. M., ZEMISHLANY, Z. AND DAVIS, K. L.: RS 86 in the treatment of Alzheimer's disease: Cognitive and biological effects. Biol. Psychiatry 22: 1067-1078, 1987.
42. HOSS, W., MESSER, W. S., MONSMA, F. J., MILLER, M. D., ELLERBROCK, B. R., SCRANTON, T., GHODSI-HOVSEPIAN, S., PRICE, M. A., BALAN, S., MAZLOUM, Z. AND BOHNETT, M.: Biochemical and behavioral evidence for muscarinic autoreceptors in the CNS. Brain Res. 517: 195-201, 1990.
43. HULME, E. C., BIRDSALL, N. J. M. AND BUCKLEY, N. J.: Muscarinic receptor subtypes. Ann. Rev. Pharmacol. Toxicol. 30: 633-673, 1990.
44. KENAKIN, T. P.: Tissue and receptor selectivity: Similarities and differences. Adv. Drug Res. 15: 71-109, 1986.
45. KENAKIN, T.: Drugs and receptors: An overview of the current state of knowledge. Drugs 40(5): 666-687, 1990.
46. KUMAR, R. AND ORGOGOZO, J.: Efficacy and safety of SB 202026 as a symptomatic treatment for Alzheimer's disease. Neurobiol. Aging 17 (4F): S161, 1996.
47. LEHERICY, S., HIRSCH, E. C., CERVERA-PIEROT, P., HERSH, L. B., BAKCHINE, S., PIETTE, F., DUYCKAERTS, C., HAUW, J-J., JAVOY-AGID, F. AND AGID, Y.: Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease. J. Comparative Neurology 330: 15-31, 1993.
48. LEVEY, A. I.: Immunological localisation of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci. 52: 441-448, 1993.
49. LEVEY, A. I., KITT, C. A., SIMONDS, W. F., PRICE, D. L. AND BRANN, M. R.: Identification and localisation of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J. Neurosci. 11(10): 3218-3226, 1991.
50. 3H]-ligand for serotonin2 receptor binding sites. Mol. Pharmacol. 21: 301-314, 1982.
51. LOUDON, J. M., HATCHER, J., STOREY, V. AND CLARK, M. S. G.: SB 202026, a functionally selective M1 partial agonist, enhances cognition at doses which do not induce side effects. Neurobiology of Aging 17 (4F): S30, 1996.
52. MACALLAN, D. R. E., LUNT, G. G., WONNACOTT, S., SWANSON, K. L., RAPOPORT, H. AND ALBUQUERQUE, E. X.: Methyllycaconitine and anatoxin-a differentiate between nicotinic receptors in vertebrate and invertebrate nervous systems. FEBS Lett. 226: 357-363, 1988.
53. MASH, D. C., FLYNN, D. D. AND POTTER, L. C.: Loss of M2 muscarinic receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science (Wash. DC) 228: 1115-1117, 1985.
54. MICHEL, A. D. AND WHITING, R. L.: Direct binding studies on ileal and cardiac muscarinic receptors. Br. J. Pharmacol. 92: 755-767, 1987.
55. NELSON, D. R., PALMER, K. J. AND JOHNSON, A. M.: Effect of prolonged 5-hydroxytryptamine uptake inhibition by paroxetine on central beta1 and beta2 adrenoceptors in rat brain. Life Sci. 47: 1683-1691, 1990.
56. 3 binding sites in rat brain cortical membranes. Biochem. Pharmacol. 38: 1893-1895, 1989.
57. NEWBERRY, N. R. AND GILBERT, M. J.: Biphasic dose-response curve to muscarine on the rat superior cervical ganglion. Eur. J. Pharmacol. 163: 237-244, 1989.
58. NEWBERRY, N. R. AND PRIESTLEY, T.: Pharmacological differences between two muscarinic responses of the rat superior cervical ganglion in vitro. Br. J. Pharmacol. 92: 817-826, 1987.
59. NEWBERRY, N. R., PRIESTLEY, T. AND WOODRUFF, G. N.: Pharmacological distinction between two muscarinic responses on the isolated superior cervical ganglion of the rat. Eur. J. Pharm. 116: 191-192, 1985.
60. OLPE, H. R., KLEBS, K., KUENG, E., CAMPICHE, P., GLATT, A., ORTMANN, R., D'AMATO, F., POZZA, M. F. AND MONDADORI, C.: Cholinomimetics induce θ rhythm and reduce hippocampal pyramidal cell excitability. Eur. J. Pharmacol. 142: 275-283, 1987.
61. ORLEK, B. S., BLANEY, F. E., BROWN, F., CLARK, M. S. G., HADLEY, M. S., HATCHER, J., RILEY, G. J., ROSENBERG, H. E., WADSWORTH, H. J. AND WYMAN, P.: Comparison of azabicyclic esters and oxadiazoles as ligands for the muscarinic receptor. J. Med. Chem. 34: 2726-2735, 1991.
62. PAXINOS, G. AND WATSON, C.: The rat brain in stereotaxic coordinates. Academic Press, Sydney, Australia, 1982.
63. PAXOS, A., HOYER, D. AND PALACIOS, J. M.: The binding of serotoninergic ligands to the porcine choroid plexus: Characterisation of a new type of serotonin recognition site. Eur. J. Pharmacol. 106: 539-546, 1984.
64. PEARCE, B. AND POTTER, L. T.: Coupling of m1 muscarinic receptors to G proteins in Alzheimer's disease. Alzheimer's Dis. Assoc. Disorders 5(3): 163-172, 1991.
65. PENN, R. D., MARTIN, E. M., WILSON, R. S., FOX, J. H. AND SAVOY, S. M.: Intraventricular bethanechol infusion for Alzheimer's disease: Results of double blind and escalating dose trials. Neurology 38: 219-222, 1988.
66. PETERS, J. A., KIRKNESS, E. F., CALLACHAN, H., LAMBERT, J. J. AND TURNER, A. J.: Modulation of the GABAa receptor by depressant barbiturates and pregnane steroids. Brit. J. Pharmacol. 94: 1257-1269, 1988.
67. PROBST, A., CORTES, R., ULRICH, J. AND PALACIOS, J. M.: Differential modification of muscarinic cholinergic receptors in the hippocampus of patients with Alzheimer's disease: An autoradiographic study. Brain Res. 450: 190-201, 1988.
68. QUIRION, R., AUBERT, I., LAPCHAK, P. A., SCHAUM, R. P., TEOLIS, S., GAUTHIER, S. AND ARAUJO, D. M.: Muscarinic receptor subtypes in human neurodegenerative disorders: Focus on Alzheimer's disease. TIPS: suppl, 80-84, Dec., 1989.
69. RICHARDS, M. H.: Rat hippocampal muscarinic autoreceptors are similar to the M2 (cardiac) subtype: Comparison with hippocampal M1, atrial M2 and ileal M3 receptors. Br. J. Pharmacol. 99: 753-761, 1990.
70. RINGDAHL, B., ROCH, M. AND JENDEN, D. J.: Regional differences in receptor reserve for analogs of oxotremorine in vivo: Implications for development of selective muscarinic agonists JPET 242(2): 464-471, 1987.
71. RINGDAHL, B.: Selectivity of partial agonists related to oxotremorine based on differences in muscarinic receptor reserve between the guinea pig ileum and urinary bladder. Mol. Pharmacol. 31: 351-356, 1987.
72. SANCHEZ, C. AND LEMBOL, H. L.: The involvement of muscarinic receptor subtypes in the mediation of hypothermia, tremor, and salivation in male mice. Pharmacol. Toxicol. 74: 35-39, 1994.
73. SCHIAVONE, A. AND BRAMBILLA, A.: Muscarinic M3 receptors mediate secretion from sweat glands in the rat. Pharmacol. Res. 23(3): 233-239, 1991.
74. SEDMAN, A. J., BOCKBRADER, H. AND SCHWARTZ, R. D.: Preclinical and Phase I clinical characterisation of CI979/RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease. Life Sci. 56(11/12): 877-882, 1995.
75. SHANNON, H. E., BYMASTER, F. P., CALLIGARO, D. O., GREENWOOD, B., MITCH, C. H., SAWYER, B. U., WARD, J. S., WONG, D. T., OLESEN, P. H., SHEARDOWN, M. J., SWEDBERG, M. D., SUZDAK, P. D. AND SAUERBERG, P.: Xanomeline: A novel muscarinic receptor agonist with functional selectivity for M1 receptors. J. Pharmacol. Exp. Ther. 269(1): 271-281, 1994.
76. SPIEGEL, R.: First results with RS 86, an orally active muscarinic agonist, in healthy subjects and in patients with dementia. In Alzheimer's Disease: Advances in Basic Research and Therapies. ed. by R. J. Wurtman, S. H. Corkin, and J. H. Growdon, pp. 391-405, the Center for Brain Sciences and Metabolism Charitable Trust, Cambridge, MA, 1984.
77. STEWART, M. AND FOX, S. E.: Do septal neurons pace hippocampal theta rhythm? TINS 13(5): 163-169, 1990.
78. SUNDARAM, K., KRIEGER, A. J. AND SAPRU, H.: M2 muscarinic receptors mediate pressor responses to cholinergic agonists in the ventrolateral medullary pressor area. Brain Res. 449: 141-149, 1988.
79. SUNDERLAND, T., TARIOT, P. N. AND NEWHOUSE, P. A.: Differential responsivity of mood, behaviour and cognition to cholinergic agents in elderly neuropsychiatric populations. Brain Res. Rev. 13: 371-389, 1988.
80. TARIOT, P. N., COHEN, R. M., WELKOWITZ, J. A., SUNDERLAND, T., NEWHOUSE, P. A., MURPHY, D. L. AND WEINGARTEN, H.: Multiple-dose arecoline infusions in Alzheimer's disease. Arch. Gen. Psychiatry 45: 901-905, 1988.
81. TERRY, R. D., MASLIAH, E., SALMON, D. P., BUTTERS, N., DETERESA, R., HILL, R., HANSEN, L. A. AND KATZMAN, R.: Physical basis of cognitive alterations in Alzheimer's disease - synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30: 572-580, 1991.
82. TRAUB, M. AND FREEDMAN, S. B.: The implication of current therapeutic approaches for the cholinergic hypothesis of dementia. Dementia 3: 189-192, 1992.
83. WAELBROECK, M., TASTENOY, M., CAMUS, J. AND CHRISTOPHE, J.: Binding of selective antagonists to four muscarinic receptors (M1 to M4) in rat forebrain. Mol. Pharmacol. 38: 267-273, 1990.
84. WETTSTEIN, A. AND SPIEGEL, R.: Clinical trials with the cholinergic drug RS 86 in Alzheimer's disease (AD) and senile dementia of the Alzheimer type (SDAT). Psychopharmacology 84: 572-573, 1984.
85. WHITEHOUSE, P. J., PRICE, D. L., STRUBLE, R. G., CLARK, A. W., COYLE, J. T. AND DELONG, M. R.: Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science (Wash. DC) 215: 1237-1239, 1982.
86. WILFFERT, B., DAVIDESKO, D., DE JONGE, A., THOOLEN, M. J. M. C., TIMMERMANS, P. B. M. W. M. AND VAN ZWIETEN, P. A.: Role of ganglionic M1 and M2 receptors in the neuronal control of the cardiovascular system of the normotensive rat as determined with pilocarpine. Eur. J. Pharmacol. 95: 109-116, 1983.
87. YAMAMURA, H. I. AND SNYDER, S.: Muscarinic cholinergic binding in rat brain. Proc. Nat. Acad. Sci. 71: 1725-1729, 1974.
88. YOUNG, P., BERGE, J., CHAPMAN, H. AND CAWTHORNE, M. A.: Novel alpha2 adrenoceptor antagonists show selectivity for alpha2A and alpha2B adrenoceptor subtypes. Eur. J. Pharmacol. 168: 381-386, 1989.